福森藥業(01652.HK)2021年收益約3.86億元 同比減少20.8%
格隆匯3月23日丨 福森藥業(01652.HK)公吿,截至2021年12月31日止年度的收益約為人民幣3.857億元,同比減少約20.8%。年度公司股權持有人應占溢利約為人民幣1660萬元;截至2021年12月31日止年度的毛利率約為54.7%,與截至2020年12月31日止年度一致。截至2021年12月31日止年度的每股基本盈利約為人民幣2分,而截至2020年12月31日止年度約為人民幣9分。
董事會已議決建議就截至2021年12月31日止年度派付末期股息每股普通股人民幣0.34分(公司截至2020年12月31日止年度的末期股息:人民幣0.46分)。
雖然面對諸多挑戰,但集團管理層仍有信心走出困境。新廠區的投產為產量提升、品質提升打下堅實基礎,同時也為新產品的生產提供了可能。集團於2021年先後恢復了鹽酸尼卡地平注射液和複方溴丙胺太林片的生產,其中鹽酸尼卡地平注射液於2021年12月在河南省牽頭的14個省份藥品聯盟採購中中標,為銷量提升打下了基礎。集團會繼續尋找有市場潛力的產品進行收購,研發或者代理銷售,逐步優化集團的產品結構。
產品研發方面,集團二甲雙胍緩釋片已經通過一致性評價,鹽酸氟桂麗嗪膠囊和酒石酸美託洛爾膠囊片兩個產品的一致性評價申請已經上報國家藥品評審中心進行評審。治療癲癇的布瓦西坦原料藥和注射液項目已經開始製劑研究工作。
中藥研發方面,集團針對現有產品的持續研究工作繼續進行;元胡止痛口服液、肝維康片已完成藥理毒理研究並發表相關學術文章。三個經典名方項目已經完成藥學研究,下一步將與重點中醫院合作開發院內製劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.